Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

STABILITY AND MOBILITY OF MAGNETIC NANOPARTICLES IN BIOLOGICAL ENVIRONMENTS DETERMINED FROM DYNAMIC MAGNETIC SUSCEPTIBILITY MEASUREMENTS.

Bohórquez AC, Unni M, Belsare S, Chiu Lam A, Rice L, Pampo C, Siemann DW, Rinaldi C.

Bioconjug Chem. 2018 Jul 16. doi: 10.1021/acs.bioconjchem.8b00419. [Epub ahead of print]

PMID:
30011185
2.

Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model.

Hughes VS, Siemann DW.

Tumor Microenviron. 2018;1(1):30-36. doi: 10.4103/tme.tme_19_17. Epub 2018 Jan 30.

3.

Tumor oxygenation and cancer therapy-then and now.

Hughes VS, Wiggins JM, Siemann DW.

Br J Radiol. 2018 Mar 14:20170955. doi: 10.1259/bjr.20170955. [Epub ahead of print]

PMID:
29513032
4.

Have Clinical Trials Properly Assessed c-Met Inhibitors?

Hughes VS, Siemann DW.

Trends Cancer. 2018 Feb;4(2):94-97. doi: 10.1016/j.trecan.2017.11.009.

PMID:
29458966
5.

Exercise and the Tumor Microenvironment: Potential Therapeutic Implications.

Wiggins JM, Opoku-Acheampong AB, Baumfalk DR, Siemann DW, Behnke BJ.

Exerc Sport Sci Rev. 2018 Jan;46(1):56-64. doi: 10.1249/JES.0000000000000137. Review.

PMID:
29166299
6.

Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.

Siemann DW, Chaplin DJ, Horsman MR.

Cancer Invest. 2017 Sep 14;35(8):519-534. doi: 10.1080/07357907.2017.1364745. Epub 2017 Sep 5.

PMID:
28872367
7.

Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.

Shenoy AK, Jin Y, Luo H, Tang M, Pampo C, Shao R, Siemann DW, Wu L, Heldermon CD, Law BK, Chang LJ, Lu J.

J Clin Invest. 2016 Nov 1;126(11):4174-4186. doi: 10.1172/JCI86623. Epub 2016 Oct 10.

8.

Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation.

Bae KM, Dai Y, Vieweg J, Siemann DW.

Am J Cancer Res. 2016 May 1;6(5):1078-88. eCollection 2016.

9.

Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.

Sudhan DR, Rabaglino MB, Wood CE, Siemann DW.

Clin Exp Metastasis. 2016 Jun;33(5):461-73. doi: 10.1007/s10585-016-9790-1. Epub 2016 Apr 7.

10.

Chemosensitizing AML cells by targeting bone marrow endothelial cells.

Bosse RC, Wasserstrom B, Meacham A, Wise E, Drusbosky L, Walter GA, Chaplin DJ, Siemann DW, Purich DL, Cogle CR.

Exp Hematol. 2016 May;44(5):363-377.e5. doi: 10.1016/j.exphem.2016.02.003. Epub 2016 Feb 16.

PMID:
26898708
11.

Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.

Sudhan DR, Pampo C, Rice L, Siemann DW.

Int J Cancer. 2016 Jun 1;138(11):2665-77. doi: 10.1002/ijc.29992. Epub 2016 Feb 5.

12.

Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

Parker EN, Song J, Kishore Kumar GD, Odutola SO, Chavarria GE, Charlton-Sevcik AK, Strecker TE, Barnes AL, Sudhan DR, Wittenborn TR, Siemann DW, Horsman MR, Chaplin DJ, Trawick ML, Pinney KG.

Bioorg Med Chem. 2015 Nov 1;23(21):6974-92. doi: 10.1016/j.bmc.2015.09.036. Epub 2015 Sep 25.

13.

Cathepsin L targeting in cancer treatment.

Sudhan DR, Siemann DW.

Pharmacol Ther. 2015 Nov;155:105-16. doi: 10.1016/j.pharmthera.2015.08.007. Epub 2015 Aug 20. Review.

14.

Modulation of the tumor vasculature and oxygenation to improve therapy.

Siemann DW, Horsman MR.

Pharmacol Ther. 2015 Sep;153:107-24. doi: 10.1016/j.pharmthera.2015.06.006. Epub 2015 Jun 11. Review.

15.

VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.

Pham K, Luo D, Siemann DW, Law BK, Reynolds BA, Hothi P, Foltz G, Harrison JK.

Cancer Lett. 2015 Apr 28;360(1):60-7. doi: 10.1016/j.canlet.2015.02.005. Epub 2015 Feb 9.

PMID:
25676691
16.

Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.

Biel NM, Siemann DW.

Cancer Lett. 2016 Oct 1;380(2):525-33. doi: 10.1016/j.canlet.2014.09.035. Epub 2014 Oct 12. Review.

17.

Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis.

Biel NM, Lee JA, Sorg BS, Siemann DW.

Vasc Cell. 2014 Aug 4;6:17. doi: 10.1186/2045-824X-6-17. eCollection 2014.

18.

In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.

Lee JA, Biel NM, Kozikowski RT, Siemann DW, Sorg BS.

Biomed Opt Express. 2014 May 28;5(6):1965-79. doi: 10.1364/BOE.5.001965. eCollection 2014 Jun 1.

19.

Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise.

McCullough DJ, Stabley JN, Siemann DW, Behnke BJ.

J Natl Cancer Inst. 2014 Apr;106(4):dju036. doi: 10.1093/jnci/dju036. Epub 2014 Mar 13.

20.

MRI-based computational model of heterogeneous tracer transport following local infusion into a mouse hind limb tumor.

Magdoom KN, Pishko GL, Rice L, Pampo C, Siemann DW, Sarntinoranont M.

PLoS One. 2014 Mar 11;9(3):e89594. doi: 10.1371/journal.pone.0089594. eCollection 2014.

21.

Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model.

Scharf VF, Farese JP, Siemann DW, Abbott JR, Kiupel M, Salute ME, Milner RJ.

Anticancer Drugs. 2014 Mar;25(3):332-9. doi: 10.1097/CAD.0000000000000061.

PMID:
24304691
22.

Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.

McCullough DJ, Nguyen LM, Siemann DW, Behnke BJ.

J Appl Physiol (1985). 2013 Dec;115(12):1846-54. doi: 10.1152/japplphysiol.00949.2013. Epub 2013 Oct 31.

23.
24.

Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice.

Scharf VF, Farese JP, Coomer AR, Milner RJ, Taylor DP, Salute ME, Chang MN, Neal D, Siemann DW.

Am J Vet Res. 2013 May;74(5):771-8. doi: 10.2460/ajvr.74.5.771.

PMID:
23627391
25.
26.

Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.

Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA.

Blood. 2013 Jan 24;121(4):707-15. doi: 10.1182/blood-2012-05-433045. Epub 2012 Dec 3.

27.

Cell-based selection provides novel molecular probes for cancer stem cells.

Sefah K, Bae KM, Phillips JA, Siemann DW, Su Z, McClellan S, Vieweg J, Tan W.

Int J Cancer. 2013 Jun 1;132(11):2578-88. doi: 10.1002/ijc.27936. Epub 2013 Feb 8.

28.

Vascular development in mouse lung metastases.

Salmon HW, Guha A, Rojiani AM, Siemann DW.

Am J Cancer Res. 2012;2(5):581-8. Epub 2012 Aug 20.

29.
30.

Src-signaling interference impairs the dissemination of blood-borne tumor cells.

Siemann DW, Dong M, Pampo C, Shi W.

Cell Tissue Res. 2012 Aug;349(2):541-50. doi: 10.1007/s00441-012-1415-7. Epub 2012 Apr 18.

31.

Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.

Molnar N, Siemann DW.

Microvasc Res. 2012 May;83(3):290-7. doi: 10.1016/j.mvr.2012.02.008. Epub 2012 Feb 23.

32.

Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.

Dai Y, Bae K, Pampo C, Siemann DW.

Clin Exp Metastasis. 2012 Mar;29(3):253-61. doi: 10.1007/s10585-011-9447-z.

PMID:
22286523
33.

Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.

Rice L, Lepler S, Pampo C, Siemann DW.

Clin Exp Metastasis. 2012 Feb;29(2):133-42. doi: 10.1007/s10585-011-9436-2. Epub 2011 Dec 1.

PMID:
22130962
34.

Another road leads to HIF-1 activation: implications for prostate cancer progression.

Dai Y, Bae K, Siemann DW.

Asian J Androl. 2012 Mar;14(2):241-2. doi: 10.1038/aja.2011.163. Epub 2011 Nov 21. No abstract available.

35.

E-cadherin plasticity in prostate cancer stem cell invasion.

Bae KM, Parker NN, Dai Y, Vieweg J, Siemann DW.

Am J Cancer Res. 2011;1(1):71-84. Epub 2010 Oct 20.

36.

Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation.

Tang M, Chen B, Lin T, Li Z, Pardo C, Pampo C, Chen J, Lien CL, Wu L, Ai L, Wang H, Yao K, Oh SP, Seto E, Smith LE, Siemann DW, Kladde MP, Cepko CL, Lu J.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15231-6. doi: 10.1073/pnas.1104662108. Epub 2011 Sep 6.

37.

Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.

Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK, Siemann DW, Horsman MR.

Int J Radiat Biol. 2011 Nov;87(11):1126-34. doi: 10.3109/09553002.2011.605418.

38.

Impact of hypoxia on the metastatic potential of human prostate cancer cells.

Dai Y, Bae K, Siemann DW.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):521-8. doi: 10.1016/j.ijrobp.2011.04.027. Epub 2011 Jun 2.

39.

Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.

Dong M, Rice L, Lepler S, Pampo C, Siemann DW.

Anticancer Res. 2010 Nov;30(11):4405-13.

PMID:
21115886
40.

Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW.

Microvasc Res. 2011 Jan;81(1):44-51. doi: 10.1016/j.mvr.2010.10.003. Epub 2010 Oct 23.

41.

Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Baguley BC, Siemann DW.

Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Review.

42.

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Siemann DW.

Cancer Treat Rev. 2011 Feb;37(1):63-74. doi: 10.1016/j.ctrv.2010.05.001. Epub 2010 Jun 8. Review.

43.

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

Dai Y, Siemann DW.

Mol Cancer Ther. 2010 Jun;9(6):1554-61. doi: 10.1158/1535-7163.MCT-10-0359. Epub 2010 Jun 1.

44.

Leukemia regression by vascular disruption and antiangiogenic therapy.

Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR.

Blood. 2010 Sep 2;116(9):1539-47. doi: 10.1182/blood-2009-06-230474. Epub 2010 May 14.

45.

Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.

Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW.

J Urol. 2010 May;183(5):2045-53. doi: 10.1016/j.juro.2009.12.092. Epub 2010 Mar 19.

46.
47.

Cell proliferation index determination by immunohistochemical detection of hCDC47 protein.

Rojiani MV, Siemann DW, Rojiani AM.

Appl Immunohistochem Mol Morphol. 2010 May;18(3):278-82. doi: 10.1097/PAI.0b013e3181c6c949.

PMID:
20048674
48.

Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.

Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR.

Blood. 2009 Nov 5;114(19):4310-9. doi: 10.1182/blood-2009-03-211342. Epub 2009 Aug 28.

49.

Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).

Siemann DW, Norris CM, Ryan A, Shi W.

Anticancer Res. 2009 Jun;29(6):1987-92.

50.

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Siemann DW, Chaplin DJ, Walicke PA.

Expert Opin Investig Drugs. 2009 Feb;18(2):189-97. doi: 10.1517/13543780802691068 . Review.

Supplemental Content

Loading ...
Support Center